Non-catalytic substrate-selective, p38alpha-specific mapk inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof

A method of treating an inflammatory disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound having the structure:

• or a pharmaceutically acceptable salt thereof, wherein,
• R5 is selected from —SO2—, —CH(OH)—, —O—, and —N(CH3)—;
• and
• L1 is selected from —CH2—, —C(CH3)2—, and —(CH2CH2)—,
• wherein the inflammatory disease is selected from rheumatoid arthritis, a cardiovascular disease, multiple sclerosis, inflammatory bowel disease, multiple sclerosis, inflammatory bowel diseases, chronic obstructive pulmonary disease, asthma, acute respiratory distress syndrome, and acute lung injury.